KELOID: Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars

Sponsor

University Hospital Inselspital, Berne (Other)

Overall Status

Withdrawn

CT.gov ID

NCT02546076

Collaborator

(none)

Enrollment

Arms

Actual Duration (Months)

Study Details

Study Description

Brief Summary

Skin injuries due to trauma are relatively common, and patients are very concerned about scars caused by trauma and primary repair. Recently, the use of ablative and non-ablative lasers based on the fractional approach has become a novel strategy for the treatment of scars.

The objective of this study is to compare the efficacy of dual-mode Er:YAG laser delivering pulses either with and without heat/coagulation in a cohort of patients with long keloid/hypertrophic scars.

The main hypothesis is that ablative fractional laser without heat/coagulation is equivalent to laser with heat/coagulation in terms of scars volume reduction, while the secondary hypothesis is that ablative fractional laser without heat/coagulation is superior in terms of post-operative erythema and hypopigmentation reduction.

Condition or Disease	Intervention/Treatment	Phase
Keloid Hypertrophic Scars	Device: Laser coagulation Device: Laser w/o coagulation	Phase 2

Detailed Description

Background

Skin injuries, such as lacerations or abrasions, due to trauma are relatively common, and patients are very concerned about scars caused by trauma and primary repair. Multiple modalities for improving the clinical appearance of scars have been attempted with varying success, including corticosteroids, dermabrasion, surgical revision, chemical peeling, silicone gel application, pressure therapy, and radiation. Lasers such as the carbon dioxide (CO2), erbium: yttrium-aluminum-garnet (Er:YAG), and pulsed dye (PDL) lasers have all been used with differing success in the treatment of scars. The goal of all these treatments is to soften depressions and stimulate neocollagenesis in order to fill in the residual defects.

Ablative lasers used for skin resurfacing, such as the CO2 and Er:YAG laser, can reduce various scars, but significant adverse effects limit their use, and patient downtime can be extensive. Owing to these potential risks, nonablative lasers have been developed as a safe alternative to ablative laser resurfacing, and have been reported to be effective and safe for scars. However outcomes have remained unsatisfactory and require several treatments to achieve satisfactory efficacy.

Recently, the use of ablative and non-ablative lasers based on the fractional approach has become a novel strategy for the treatment of scars, and some authors have suggested that treatment with fractional lasers for various scars, such as postoperative, atrophic, and acne scars, has been demonstrated to safely improve the appearance of the scars. However, there is a lack of studies comparing coagulation modality of such lasers.

Objective

Methods

This is a single center, investigator initiated, double blind, within-subject split-lesion design, equivalence randomized clinical study.

Consecutive patients, referring to Dermatology outpatient and fulfilling inclusion criteria, are included. Participants are then randomly assigned to get treatment with Er:YAG laser on half of scar section side by equally splitting the lesion area in two symmetric and uniform parts. One side will be treated with coagulation while the other one will be without. In case of multiple lesions per patient, only the largest and most uniform one is selected for the study purpose.

Study Design

Study Type:

Interventional

Actual Enrollment :

0 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Outcomes Assessor)

Primary Purpose:

Treatment

Official Title:

Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars

Actual Study Start Date :

May 1, 2016

Actual Primary Completion Date :

Jan 1, 2017

Actual Study Completion Date :

Jan 1, 2017

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Laser coagulation Er:YAG laser treatment with coagulation modality	Device: Laser coagulation The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
Active Comparator: Laser w/o coagulation Er:YAG laser treatment without coagulation modality	Device: Laser w/o coagulation The treatment consists in performing Er:Yag laser with true pulsed Erbium mode

Arm

Intervention/Treatment

Active Comparator: Laser coagulation

Er:YAG laser treatment with coagulation modality

Device: Laser coagulation

The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode

Active Comparator: Laser w/o coagulation

Er:YAG laser treatment without coagulation modality

Device: Laser w/o coagulation

The treatment consists in performing Er:Yag laser with true pulsed Erbium mode

Outcome Measures

Primary Outcome Measures

Any reduction from baseline of scars volume as assessed by image analysis [24 weeks]

Secondary Outcome Measures

Any reduction from baseline of scars volume as assessed by image analysis [4, 8, 12, 16, 24 weeks]
Any improvement of scars as assessed by physician according to an ordinal 6-points scale [4, 8, 12, 16, 24 weeks]
Overall patient satisfaction to the proposed therapy as assessed by visual analogue scale [16, 24 weeks]
Erythema index as assessed by image analysis [4, 8, 12, 16, 24 weeks]
Hypopigmentation as assessed by image analysis [4, 8, 12, 16, 24 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Given written informed consent
Skin type I-IV
Presence of long keloid/hypertrophic scar of at least 3 cm² and of uniform/symmetric type
Willingness and ability to adhere study protocol

Exclusion Criteria